Triphenyl phosphate

Repeated dose toxicity: other routes

Administrative data

Endpoint:

sub-chronic toxicity: other route

Type of information:

experimental study

Adequacy of study:

other information

Reliability:

3 (not reliable)

Rationale for reliability incl. deficiencies:

other: Early study; one dose level only, standard endpoints missing; not all observed parameters reported TS not characterised; Also assessed by OECD.

Data source

Reference

Reference Type:

publication

Title:

Vergleichende toxikologische Untersuchung von Triphenylphosphat und Trikresylphosphat. [Comparative toxicological studies on triphenylphosphate and tricresylphosphate].

Author:

Hierholzer K, Noetzel H, Schmidt L

Year:

1957

Bibliographic source:

Arzneimittelforschung 7(10), 585–588

Materials and methods

Principles of method if other than guideline:

Method: other: Parameters measured were body weight and food consumption. A necropsy was performed on all rats on study. The heart, lungs, kidneys, adrenal gland, intestines, brain, spine, peripheral nerves and muscle were examined histologically.

GLP compliance:

no

Test material

Test material information

Constituent 1

Reference substance name:

Triphenyl phosphate

EC Number:

204-112-2

EC Name:

Triphenyl phosphate

Cas Number:

115-86-6

Molecular formula:

C18H15O4P

IUPAC Name:

triphenyl phosphate

Test animals

Species:

rat

Strain:

not specified

Sex:

male/female

Administration / exposure

Route of administration:

other: oral

Duration of treatment / exposure:

2 months

Frequency of treatment:

daily

Doses / concentrations

Remarks:

Doses / Concentrations:
1000 mg/kg bw/day

No. of animals per sex per dose:

9 treated and 3 control rats

Control animals:

yes, concurrent vehicle

Details on study design:

Post-exposure period: no

Results and discussion

Target system / organ toxicity

Critical effects observed:

not specified

Any other information on results incl. tables

MORTALITY: Three rats died on the 14th day and one on the 25th day. 
OBSERVATION: All treated animals had reduced appetite and
growth rate, neglected fur
BODY WEIGHT: severely reduced body weight gain throughout the study
NECROPSY: no pathologic findings
HISTOPATHOLOGY: pyknotic or swollen ganglionic cells in the spinal cord  with vacuole formation; vacuole formation in peripheral nerves. No  changes were observed in the myelin sheaths. 
effects in liver and kidneys (reduced glycogen storage,
single cell necroses, hyaline casts, fatty degeneration in
tubuli)are ascribed to the reduced general condition

Applicant's summary and conclusion

Conclusions:

MORTALITY: Three rats died on the 14th day and one on the 25th day. OBSERVATION: All treated animals had reduced appetite and growth rate, neglected fur BODY WEIGHT: severely reduced body weight gain throughout the study NECROPSY: no pathologic findings HISTOPATHOLOGY: pyknotic or swollen ganglionic cells in the spinal cord with vacuole formation; vacuole formation in peripheral nerves. No changes were observed in the myelin sheaths. effects in liver and kidneys (reduced glycogen storage, single cell necroses, hyaline casts, fatty degeneration in tubuli)are ascribed to the reduced general condition.

Executive summary:

Rats were administered TPP at dose levels of 1000 mg/kg bw/day for 2 months daily. Mortality: Three rats died on the 14th day and one on the 25th day. Observation showed all treated animals had reduced appetite, growth rate and neglected fur. Body weight gain was severely reduced throughout the study. At necropsy no pathologic findings. Histopathology revealed pyknotic or swollen ganglionic cells in the spinal cord with vacuole formation; vacuole formation in peripheral nerves. No changes were observed in the myelin sheaths. Effects in liver and kidneys (reduced glycogen storage, single cell necroses, hyaline casts, fatty degeneration in tubuli)are ascribed to the reduced general condition.